secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001534120-25-000013
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo completes Phase 2 LOTUS enrollment for AVTX-009; topline data mid-2026
----------------------------------------------------------------------------

- Enrolled ~250 patients, exceeding the 222-patient target.
- Trial is randomized, double-blind, placebo-controlled with two AVTX-009 dose regimens.
- Primary endpoint is HiSCR75 at Week 16; topline results expected mid-2026.
- CEO Dr. Garry Neil cited strong investigator and patient engagement due to high unmet need.
- Trial identifier NCT06603077; details at clinicaltrials.gov or lotustrial.com.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000013/0001534120-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000013/avtx-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001534120-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer